Biliary Tract Neoplasms Clinical Trial
Official title:
The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer
This is a prospective cohort study. Patients who meet the inclusion criteria will be enrolled in this study. The samples of biliary tract tumors will be collected. Genome sequencing, mini-PDX and PDX will be performed according to the requirement of individualized precision therapy programs. Suitable drugs will be chose according to drug screening results. OS and PFS will be compared with traditional chemotherapy to evaluate the effect of individualized precision therapy programs.
In this prospective cohort study, patients who are eligible for inclusion criteria will
enroll in the study. After bile duct tumor samples were collected, whole genome sequencing,
drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided
according to the different genomics classification, and then to develop individualized
precise treatment programs.
The investigators hope to achieve the following objectives:
① Through the establishment of Individualized Precision Therapy Programs to improve the
overall survival of bile duct malignancy (BTC)；
② To study the molecular typing of the prognosis of biliary malignancy;
③ To construct a database of BTC gene bank, as well as for drug screening information.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
| Completed |
NCT03101566 -
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05237193 -
A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
|
||
| Not yet recruiting |
NCT06037655 -
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
|
Phase 2 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Completed |
NCT00196105 -
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
|
N/A | |
| Completed |
NCT02558959 -
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT02829918 -
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
|
Phase 2 | |
| Completed |
NCT02784353 -
Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy
|
N/A | |
| Recruiting |
NCT05429203 -
Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
|
N/A | |
| Recruiting |
NCT02255669 -
Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction
|
N/A | |
| Completed |
NCT01731821 -
Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
|
Phase 3 | |
| Completed |
NCT00422409 -
Endoscopic Stenting of Gastrointestinal Cancer
|
N/A | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Recruiting |
NCT03063554 -
EUS BD vs ERCP TP for Pancreatic Cancer
|
N/A | |
| Terminated |
NCT02615210 -
Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures
|
N/A | |
| Completed |
NCT04595058 -
LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent
|
N/A | |
| Recruiting |
NCT04856761 -
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
|
||
| Recruiting |
NCT03427242 -
Apatinib for Advanced Biliary Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05615818 -
Personalized Medicine for Advanced Biliary Cancer Patients
|
Phase 3 |